Is lenvatinib/lenvatinib (Lenvima) a targeted drug or an immune drug?

Lenvatinib is a typical small molecule targeted drug, not an immunotherapy drug. It inhibits multiple receptor tyrosine kinase (RTK) signaling pathways and blocks the angiogenesis and proliferation of tumor cells, thereby achieving anti-tumor effects. Its targets include vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor α (PDGFRα) and RET, etc. These targets are closely related to tumor growth, metastasis and microenvironment formation. By precisely inhibiting these signaling pathways, lenvatinib can effectively control tumor angiogenesis, block tumor nutrient supply, and delay disease progression.

Different from immune drugs, immunotherapy mainly identifies and eliminates cancer cells by activating or regulating the patient's own immune system. For example,PD-1/PD-L1 or CTLA-4 antibodies can relieve the suppression of the immune system by tumors. Lenvatinib, on the other hand, acts directly on tumor cells and their microenvironment, achieving anti-tumor effects by inhibiting key signaling pathways and does not rely on activating the immune system, so it is a classic targeted therapy drug.

In clinical practice, lenvatinib is often used in combination with immune drugs to enhance its efficacy. For example, in advanced renal cell carcinoma or endometrial cancer, lenvatinib can be used in combination with Pembrolizumab. While the targeted drug controls tumor angiogenesis, the immune drug activates the body's immune response to achieve a dual synergistic effect. This combination treatment strategy not only retains the targeting properties of lenvatinib, but also fully utilizes the anti-tumor potential of immune drugs, providing patients with a more effective treatment option.

In general, the core mechanism of lenvatinib is to precisely target the signaling pathway of tumor-related receptors. Its therapeutic properties, mode of administration, and mechanism of action are significantly different from immunotherapy drugs.

Reference materials:https://www.lenvima.com/